Post by Oncidium foundation

𝗪𝗵𝗮𝘁 𝘀𝘁𝗮𝗻𝗱𝘀 𝗯𝗲𝘁𝘄𝗲𝗲𝗻 𝗮 𝗰𝗮𝗻𝗰𝗲𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗮𝗻𝗱 𝗮 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘁𝗵𝗮𝘁 𝗰𝗼𝘂𝗹𝗱 𝗰𝗵𝗮𝗻𝗴𝗲 𝘁𝗵𝗲𝗶𝗿 𝗼𝘂𝘁𝗰𝗼𝗺𝗲? 𝗢𝗳𝘁𝗲𝗻, 𝗶𝘁 𝗶𝘀 𝘀𝗶𝗺𝗽𝗹𝘆 𝘄𝗵𝗲𝗿𝗲 𝘁𝗵𝗲𝘆 𝗹𝗶𝘃𝗲.   A landmark new open-access study in the Indian Journal of Nuclear Medicine offers a first look at that gap. The BRICS Multicentre Theragnostic Survey 2026 is the first study of its kind, gathering data from 137 nuclear medicine centres across 14 countries that represent nearly half the world's population.   These are major centres already engaged in theranostics. And yet, even among them, the obstacles are striking: unreliable radionuclide supply, reimbursement and funding gaps, and a shortage of trained specialists. If the better-equipped centres face these hurdles, the barriers facing everyone else are far higher.   The most hopeful signal? More than 95% of participating centres said they are ready to collaborate on research, training, and shared protocols.   Equitable access to radioligand therapy is not a luxury. For patients facing cancer, it is a matter of survival.   📄Read the article: https://lnkd.in/ehApE5aq #Theranostcis #Theragnostics #RadioligandTherapy #NuclearMedicine #HealthEquity #Access #CancerCare